Free Trial
→ Trump goes 'all-in' on Grand Canyon energy breakthrough (From Behind the Markets) (Ad)tc pixel
NASDAQ:NAGE

Niagen Bioscience Q3 2025 Earnings Results & Report

Niagen Bioscience logo
$2.63 -0.06 (-2.23%)
Closing price 04:00 PM Eastern
Extended Trading
$2.62 0.00 (-0.19%)
As of 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Niagen Bioscience beat analyst expectations on both earnings and revenue in its Q3 2025 results, released November 4, 2025. The company reported EPS of $0.05 versus the $0.02 consensus estimate, while revenue of $33.99 million topped the $31.30 million estimate by $2.69 million.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q3 2025
Report Date
Time
After Market Closes

Niagen Bioscience EPS Results

Actual EPS
$0.05
Consensus EPS
$0.02
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

Niagen Bioscience Revenue Results

Actual Revenue
$33.99 million
Expected Revenue
$31.30 million
Beat/Miss
Beat by +$2.69 million
YoY Revenue Growth
N/A

Conference Call Resources

Niagen Bioscience Q3 2025 Earnings FAQ

Niagen Bioscience (NASDAQ:NAGE) reported earnings of $0.05 per share for Q3 2025, beating the consensus estimate of $0.02. The report was announced on Tuesday, November 4, 2025.

Niagen Bioscience reported revenue of $33.99 million for Q3 2025, against a consensus estimate of $31.30 million.

Niagen Bioscience Earnings Headlines

Comparing Unicharm (OTCMKTS:UNICY) & Niagen Bioscience (NASDAQ:NAGE)
October 10 at 3:45 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31105475
Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, Honored with the 2026 Annette Dickinson Trailblazer Award by Radicle ...
October 8, 2026  |  marketscreener.comM
Why This Overlooked Mineral Could Define AI's Future
China controls 90% of the production of two critical minerals essential to AI data centers, semiconductors, and quantum computing. In 2024, AI data centers consumed as much energy as New York and Chicago combined, underscoring the urgency of securing domestic supply. Jamie Dimon and Condoleezza Rice are now backing Project Phoenix, a major push to rebuild America's mineral supply chain.tc pixel
October 12 at 1:00 AM  |  Weiss Ratings (Ad)
Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, Honored with the 2026 Annette Dickinson Trailblazer Award by Radicle Science and Council for Responsible Nutrition (CRN)
October 8, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261008014757/en/andrew-shao-ph.d.-senior-vice-president-of-global-regulatory-and-scientific-affairs-at-niagen-bioscience-honored-with-the-2026-annette-dickinson-trailblazer-award-by-radicle-science-and-council-for-responsible-nutrition-crn/
Analysts Offer Insights on Consumer Goods Companies: Niagen Bioscience (NAGE) and Target (TGT)
October 6, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/TGT/pressreleases/4978970/analysts-offer-insights-on-consumer-goods-companies-niagen-bioscience-nage-and-target-tgt/
Niagen Bioscience to Present at LD Micro 20th Annual Main Event
October 6, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261006449816/en/Niagen-Bioscience-to-Present-at-LD-Micro-20th-Annual-Main-Event/
See More Niagen Bioscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Niagen Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Niagen Bioscience and other key companies, straight to your email.

About Niagen Bioscience

Niagen Bioscience (NASDAQ:NAGE) is a life sciences company focused on products and technologies designed to support healthy aging and cellular health. The company’s principal technology is nicotinamide riboside (NR), a form of vitamin B3 that serves as a precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme involved in cellular energy production and other biological processes.

The company develops and commercializes NIAGEN-branded NR ingredients for use in dietary supplements, functional foods and beverages, and other consumer health products. Its consumer portfolio includes Tru Niagen, a direct-to-consumer supplement brand, while its ingredient business supplies NIAGEN products to manufacturers and brand partners. The company also supports its products with scientific research, quality testing and intellectual-property licensing.

Niagen Bioscience was formerly known as ChromaDex Corporation and has been associated with research and commercialization efforts involving NAD+ biology and NR. Its products are marketed through online channels, retail distribution and commercial partners in the United States and international markets. The company is led by Chief Executive Officer Rob Fried.

View Niagen Bioscience Profile
Earnings Tools